Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Sheep / IgG|
|Immunogen||Recombinant human interferon alpha A|
|Storage buffer||whole serum|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Neutralization (Neu)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Specificity: Neutralizes human interferon alpha.
Activity: Interferon was titrated with the use of the cytopathic effect inhibition assay, where 1 unit/ml of interferon was necessary to produce an endpoint of 50%. One neutralization unit is defined as the amount of serum required to neutralize one unit of human IFN alpha to an endpoint of 50%.
Store at -20°C for short-term use (less than 6 months). For long-term storage, aliquot and store at -70°C or below for retention of full activity. Refreezing should be done on dry ice or in a dry ice/alcohol bath. Further dilution of the product should be in buffers containing protein such as 0.1% BSA.
Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by “Natural IFN-producing cells" (IPCs) as part of the host immune response and can also inhibit the development of tumors. IFN-beta binding by its receptor results in the activation of the tyrosine kinases Jak1 and Tyk2 and phosphorylation of members of the STAT family of transcription factors, leading to the transcription and expression of the immune response genes. More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta. IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
RNA sensors enable human mast cell anti-viral chemokine production and IFN-mediated protection in response to antibody-enhanced dengue virus infection.
311001 was used in blocking or activating experiment to study the role of RNA sensor proteins in the early detection and response to antibody-enhanced dengue virus infection by mast cells
|Brown MG,McAlpine SM,Huang YY,Haidl ID,Al-Afif A,Marshall JS,Anderson R||PloS one (7:null)||2012|
IFN-α production by human mononuclear cells infected with varicella-zoster virus through TLR9-dependent and -independent pathways.
311001 was used in immunocytochemistry to investigate the effect of varicella-zoster virus infection on interferon alpha expression in mononuclear cells
|Yu HR,Huang HC,Kuo HC,Sheen JM,Ou CY,Hsu TY,Yang KD||Cellular & molecular immunology (8:181)||2011|
Measles virus-induced modulation of host-cell gene expression.
311001 was used in ELISA to study measles virus-induced modulation of host-cell gene expression by human peripheral blood mononuclear cells
|Bolt G,Berg K,Blixenkrone-Møller M||The Journal of general virology (83:1157)||2002|
Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity.
311001 was used in ELISA and western blot to study the enhanced immunogenicity of recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B
|Luo Y,Chen X,Han R,O'Donnell MA||Clinical and experimental immunology (123:264)||2001|
IFN-alpha 1b; IFN-alpha-1/13; interferon alpha 1b; interferon alpha-1/13; interferon alpha-D; interferon, alpha 1; interferon-alpha1; leIF D
IFL; IFN; IFN-ALPHA; IFN-alphaD; IFNA1; IFNA13; IFNA@